May 14 (Reuters) -

The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder, the company said on Tuesday.

The FDA is now set to make its decision known by Aug. 14, compared to its previous action date set for May 14.

(Reporting by Sriparna Roy and Sneha S K in Bengaluru; Editing by Krishna Chandra Eluri and Shailesh Kuber)